Avinger announces closing of up to $24 million public offering

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked series warrants redwood city, ca / accesswire / june 17, 2024 / avinger, inc. (nasdaq:avgr), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closing its previously announced public offering of an aggregate of 3,614,457 shares of its common stock (or common stock equivalents in lieu thereof), series a-1 warrants to purchase up to 3,614,457 shares of common stock, series a-2 warrants to purchase up to 3,614,457 shares of common stock and series a-3 warrants to purchase up to 3,614,457 shares of common stock (all the warrants, collectively, the "series warrants"), at a combined public offering price of $1.66 per share (or per common stock equivalent in lieu thereof) and accompanying series warrants. the series warrants have an exercise price of $1.66 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the series warrants.
AVGR Ratings Summary
AVGR Quant Ranking